NBIX

🏥 Healthcare

Neurocrine Biosciences, Inc.

Conservative #32Aggressive #253Low Risk

$128.63-1.13%

Day High$130.34

Day Low$127.16

Volume1.1M

Mkt Cap$12.9B

52W Low $8452W High $160

Market Cap

$12.5B

P/E Ratio

26.5

Sector avg: 19.1

Rev Growth

21.4%

Sector avg: 8.0%

Earnings Growth

40.2%

Profit Margin

16.7%

Sector avg: 16.9%

Debt/Equity

0.13

Score Breakdown

Overall Score81.1

Fundamental Score73.1

ML Score88.4

Score by Horizon

3 Month

74.0

6 Month

82.7

Primary

1 Year

87.0

Quality Assessment

Earnings Grade

Strong fundamentals, high earnings quality

Position Sizing

Suggested Allocation

Confidence

high

Analysis Signals

Positive Signals

Fundamental: 73.1 (sector-relative)

ML percentile=88.4 (pre-ranked by batch)

Procyclicality dampener: ML weight reduced to 9.0% (S&P 500 return=25.0% > 20% (extended rally); Yield curve inverted (-10bp) — recession signal; Late-cycle score 2/3 → ML weight ×0.90)

Blend: 91% fund (73.1) + 9% ML (88.4) = 74.5

Market-cap adj: +2.0pt ($12.5B)

Risk Signals

Risk (low): Very low vol 6.6% → +8.8pt stability bonus; Drawdown 18% → -4.2pt

Sector Peer Comparison(Healthcare — 11 stocks in universe)

Stock	Score	P/E	Rev Growth	Margin	Mkt Cap
NBIXNeurocrine Biosciences, Inc.	81.1	26.5	21.4%	16.7%	$12.5B
GMABGenmab A/S	90.3	13.1	22.8%	36.4%	$18.5B
EXELExelixis, Inc.	83.5	15.1	7.0%	33.7%	$11.7B
SNYSanofi	83.4	9.1	5.5%	18.2%	$113.6B
GEHCGE HealthCare Technologies Inc.	80.5	17.7	4.8%	10.1%	$36.6B
ALKSAlkermes plc	80.0	16.5	-6.4%	23.9%	$5.5B
Sector Average	79.0	19.1	8.0%	16.9%	—

Why This Stock

HealthcareStrong revenue growthHealthy profit marginHigh quality

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.